Suppr超能文献

针对布鲁氏菌 IV 型分泌系统(T4SS)的多表位疫苗候选物的设计。

Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS).

机构信息

The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.

Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Xinjiang, China.

出版信息

PLoS One. 2023 Aug 10;18(8):e0286358. doi: 10.1371/journal.pone.0286358. eCollection 2023.

Abstract

Brucellosis is a common zoonosis, which is caused by Brucella infection, and Brucella often infects livestock, leading to abortion and infertility. At present, human brucellosis remains one of the major public health problems in China. According to previous research, most areas in northwest China, including Xinjiang, Tibet, and other regions, are severely affected by Brucella. Although there are vaccines against animal Brucellosis, the effect is often poor. In addition, there is no corresponding vaccine for human Brucellosis infection. Therefore, a new strategy for early prevention and treatment of Brucella is needed. A multi-epitope vaccine should be developed. In this study, we identified the antigenic epitopes of the Brucella type IV secretion system VirB8 and Virb10 using an immunoinformatics approach, and screened out 2 cytotoxic T lymphocyte (CTL) epitopes, 9 helper T lymphocyte (HTL) epitopes, 6 linear B cell epitopes, and 6 conformational B cell epitopes. These advantageous epitopes are spliced together through different linkers to construct a multi-epitope vaccine. The silico tests showed that the multi-epitope vaccine was non-allergenic and had a strong interaction with TLR4 molecular docking. In immune simulation results, the vaccine construct may be useful in helping brucellosis patients to initiate cellular and humoral immunity. Overall, our findings indicated that the multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for the development of a Brucella vaccine.

摘要

布鲁氏菌病是一种常见的人畜共患病,由布鲁氏菌感染引起,布鲁氏菌常感染家畜,导致流产和不孕。目前,人类布鲁氏菌病仍是中国主要的公共卫生问题之一。根据以往的研究,包括新疆、西藏等在内的中国西北地区大部分地区均受到布鲁氏菌的严重影响。尽管有针对动物布鲁氏菌病的疫苗,但效果往往不佳。此外,针对人类布鲁氏菌感染还没有相应的疫苗。因此,需要寻找一种新的早期预防和治疗布鲁氏菌的策略。应该开发一种多表位疫苗。在本研究中,我们使用免疫信息学方法鉴定了布鲁氏菌 IV 型分泌系统 VirB8 和 Virb10 的抗原表位,并筛选出 2 个细胞毒性 T 淋巴细胞 (CTL) 表位、9 个辅助性 T 淋巴细胞 (HTL) 表位、6 个线性 B 细胞表位和 6 个构象 B 细胞表位。这些有利的表位通过不同的接头拼接在一起,构建成一种多表位疫苗。计算机模拟测试表明,多表位疫苗无过敏原性,与 TLR4 分子对接具有很强的相互作用。在免疫模拟结果中,疫苗构建物可能有助于布鲁氏菌病患者启动细胞和体液免疫。总体而言,我们的研究结果表明,多表位疫苗构建物具有高质量的结构和合适的特性,可为布鲁氏菌疫苗的开发提供理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0d2/10414599/19428224e651/pone.0286358.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验